Top

Published in:

Open Access 01-06-2021 | Multiple Myeloma | Letter to the Editor

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab

Authors: Khalid Shoumariyeh, Johannes Jung, Michael Rassner, Sandra Maria Dold, Veronika Riebl, Milena Pantic, Georg Herget, Reinhard Marks, Michael Lübbert, Ralph Wäsch, Monika Engelhardt

Published in: Annals of Hematology | Issue 6/2021

Excerpt

Dear Editor, …

Available only for authorised users

Leone G, Pagano L, Ben-Yehuda D, Voso MT (2007) Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 92:1389–1398. https://doi.org/10.3324/haematol.11034CrossRefPubMed

Engelhardt M, Ihorst G, Landgren O, Pantic M, Reinhardt H, Waldschmidt J, May AM, Schumacher M, Kleber M, Wasch R (2015) Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. Haematologica. 100:1340–1349. https://doi.org/10.3324/haematol.2015.127548CrossRefPubMedPubMedCentral

Engelhardt M, Domm A-S, Dold SM, Ihorst G, Reinhardt H, Zober A, Hieke S, Baayen C, Müller SJ, Einsele H, Sonneveld P, Landgren O, Schumacher M, Wäsch R (2017) A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 102:910–921. https://doi.org/10.3324/haematol.2016.162693CrossRefPubMedPubMedCentral

Dold SM, Riebl V, Wider D, Follo M, Pantic M, Ihorst G et al (2020) Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma. Haematologica. 105:e523. https://doi.org/10.3324/haematol.2019.238394CrossRefPubMedPubMedCentral

Stratmann J, van Kann E, Rummelt C, Koschade S, Röllig C, Lübbert M, Schaich M, Parmentier S, Sebastian M, Chromik J, Becker von Rose A, Ballo O, Steffen B, Serve H, Brandts C, Shaid S (2019) Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: a well-tolerated and effective treatment after hypomethylating-agent failure. Leuk Res 85:106192. https://doi.org/10.1016/j.leukres.2019.106192CrossRefPubMed

Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW et al (2020) DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 34:938–941. https://doi.org/10.1038/s41375-019-0587-5CrossRefPubMed

García-Guerrero E, Gogishvili T, Danhof S, Schreder M, Pallaud C, Pérez-Simón JA, Einsele H, Hudecek M (2017) Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood. 129:3386–3388. https://doi.org/10.1182/blood-2017-03-770776CrossRefPubMed

Bat-Erdene A, Nakamura S, Oda A, Iwasa M, Teramachi J, Ashtar M, Harada T, Miki H, Tenshin H, Hiasa M, Fujii S, Sogabe K, Oura M, Udaka K, Kagawa K, Yoshida S, Aihara KI, Kurahashi K, Endo I, Abe M (2019) Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA. Br J Haematol 185:969–974. https://doi.org/10.1111/bjh.15673CrossRefPubMed

Zhao C, Jia B, Wang M, Schell TD, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Songdej N, Sivik JM, Hohl RJ, Zeng H, Zheng H (2020) Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. Br J Haematol 188:674–684. https://doi.org/10.1111/bjh.16228CrossRefPubMed

10.

Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT (2018) Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 131(9):995–999. https://doi.org/10.1182/blood-2017-07-794214CrossRefPubMedPubMedCentral

11.

Naik J, Themeli M, de Jong-Koorlar R, Ruiter RWJ, Poddighe PJ, Yuan H et al (2019) CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica. 104(3):e100–e103. https://doi.org/10.3324/haematol.2018.192757CrossRefPubMedPubMedCentral

12.

Berthon C, Nudel M, Boyle EM, Goursaud L, Boyer T, Marceau A, Quesnel B (2020) Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size. Leuk Res Rep 13:100202. https://doi.org/10.1016/j.lrr.2020.100202CrossRefPubMedPubMedCentral

Title: Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Authors: Khalid Shoumariyeh
Johannes Jung
Michael Rassner
Sandra Maria Dold
Veronika Riebl
Milena Pantic
Georg Herget
Reinhard Marks
Michael Lübbert
Ralph Wäsch
Monika Engelhardt
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Myeloma
Acute Myeloid Leukemia
Fluorescence in Situ Hybridization
Daratumumab
Published in: Annals of Hematology / Issue 6/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-021-04490-3

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

ACC 2024 Congress

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2021

Very rare lineage switch from acute myeloid leukemia with BCR-ABL1 to B-lymphoblastic leukemia

Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)

Paroxysmal nocturnal haemoglobinuria associated with a novel phosphatidylinositol glycan class A (PIGA) mutation in a patient with Klinefelter syndrome

Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant

Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study